miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2020.05.007

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (5): 369-373.doi: 10.3969/j.issn.1004-616x.2020.05.007

miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义

邵俊国¹, 焦文静¹, 王雪晓², 张金艳¹, 马鸣¹

1. 河北医科大学第四医院检验科, 河北石家庄 050011;
2. 河北医科大学第四医院肿瘤免疫科, 河北石家庄 050011

收稿日期:2020-04-18 修回日期:2020-09-07 出版日期:2020-10-01 发布日期:2020-10-12
通讯作者: 马鸣,E-mail:maming19830419@163.com E-mail:maming19830419@163.com
作者简介:邵俊国,E-mail:sjg636688@163.com。
基金资助:
国家自然科学基金（81703073）；河北省自然科学基金（H2018206 115）；河北省卫健委重点资助项目（20130254）

Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues

SHAO Junguo¹, JIAO Wenjing¹, WANG Xuexiao², ZHANG Jinyan¹, MA Ming¹

1. Department of Laboratory, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011;
2. Department of Tumor Immunity, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2020-04-18 Revised:2020-09-07 Online:2020-10-01 Published:2020-10-12

摘要/Abstract

摘要： 目的：研究miR-429和Bmi-1 mRNA在肺癌（LC）组织中的表达及其与患者临床特征、预后之间的关系，并探讨其表达水平对LC患者预后的预测意义。方法：选取2013年1─12月在河北医科大学第四医院就诊的60例LC患者癌组织及癌旁组织，实时荧光定量PCR（qPCR）技术检测组织中miR-429及Bmi-1 mRNA的表达水平，并分析二者之间表达水平的关系及其与患者临床病理指标及预后之间的关系。结果：与癌旁组织比较，LC组织中miR-429表达水平明显降低，而Bmi-1 mRNA的表达水平明显升高（P < 0.01）。LC组织中miR-429低表达而Bmi-1 mRNA高表达的患者往往瘤组织较大、临床分期较晚、更易发生淋巴结转移，同时患者生存期较短。结论：LC组织中低表达miR-429及高表达Bmi-1 mRNA可能是患者临床进展及预后较差的预测指标。

关键词: miR-429, Bmi-1, 肺癌, 预后, 临床意义

Abstract: OBJECTIVE: To study the clinical significance of the expression of miR-429 and Bmi-1 in lung carcinoma (LC) tissues. METHODS: Samples of tumor tissues and paraplastic tissues were collected from 60 LC patients,January to December,2013. Expression of miR-429 and Bmi-1 mRNA in both tissues were detected by the quantitative real-time PCR (qPCR) assay. In addition,their relationships with clinical features and prognosis of the patients were analysed. RESULTS: The tumor tissues showed significantly decreased expression of miR-429 and increased expression of Bmi-1,compared with the paraplastic tissues (P < 0.01). Among the patients,those with lower expression of miR-429 and higher expression of Bmi-1 in their tumor tissues tended to have larger tumors,later clinical stages,more prone to lymph node metastasis and shorter survival time. CONCLUSION: The results show that the LC patients with lower miR-429 expression and/or higher Bmi-1 expression in tumour tissues frequently had worse clinical outcomes and poorer prognoses.

Key words: miR-429, Bmi-1, lung carcinoma, prognosis, clinical significance

中图分类号:

R734.2

邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.

SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.

参考文献

[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2] XIAO Y, YAN W, LU L, et al. p38/p53/miR-200a-3p feedback loop promotes oxidative stress-mediated liver cell death[J]. Cell Cycle, 2015, 14(10):1548-1558.
[3] YANG X X, SANG M X, ZHU S C, et al. Radiosensitization of esophageal carcinoma cells by the silencing of BMI-1[J]. Oncol Rep, 2016, 35(6):3669-3678.
[4] 马鸣, 栾亦然, 白函瑜, 等. 微RNA-429通过抑制Bmi-1表达提高食管鳞癌细胞的化疗敏感性[J]. 肿瘤, 2019, 39(12):993-1003.
[5] 马鸣, 魏思思, 武一鹏, 等. Mda-7/IL-24与C-myb在Burkitt淋巴瘤中的表达及其相关性研究[J]. 免疫学杂志, 2017, 33(8):691-696.
[6] ZHOU X, MEN X, ZHAO R, et al. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer[J]. Cancer Gene Ther, 2018, 25(3):68-76.
[7] TAMAGAWA S, BEDER L B, HOTOMI M, et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma[J]. Int J Mol Med, 2014, 33(4):879-886.
[8] FAN L, WANG J, CAO Q, et al. Aberrant miR-1246 expression promotes radioresistance in non-small cell lung cancer:a potential prognostic biomarker and radiotherapy sensitization target[J]. Am J Cancer Res, 2020, 10(1):314-335.
[9] LI J, XU X, WEI C, et al. Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis[J]. Int J Clin Exp Pathol, 2020, 13(1):1-13.
[10] MA M, ZHAO L, SUN G, et al. Mda-7/IL-24 enhances sensitivity of B cell lymphoma to chemotherapy drugs[J]. Oncol Rep, 2016, 35(5):3122-3130.
[11] YANG X X, MA M, SANG M X, et al. BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway[J]. Oncol Rep, 2018, 39(2):667-678.
[12] GLOUSHANKOVA N A. Changes in regulation of cell-cell adhesion during tumor transformation[J]. Biochemistry (Mosc), 2008, 73(7):742-750.
[13] 栾亦然, 刘丽源, 皎龙, 等. MiR-429及Bmi-1 mRNA在弥漫性大B细胞淋巴瘤中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(3):177-181.
[14] HUR K, TOIYAMA Y, TAKAHASHI M, et al. microRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis[J]. Gut, 2013, 62(9):1315-1326.

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[8]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[9]	赵俊伟, 华辰凤, 尚平平, 谢复炜, 李翔. 亚砷酸As (Ⅲ)诱导人肺癌A549细胞氧化应激反应的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 28-31.
[10]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[11]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[12]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[13]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[14]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[15]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.

miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义

Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价